Progress in the application of PD-(L)1 PET-targeted nuclide probes for tumor immunotherapy-related studies / 中华放射医学与防护杂志
Chinese Journal of Radiological Medicine and Protection
; (12): 158-162, 2024.
Article
in Zh
| WPRIM
| ID: wpr-1027405
Responsible library:
WPRO
ABSTRACT
Immunotherapy has entered the clinical treatment for various tumors, among which the blockade therapy of PD-1/PD-L1 immune checkpoint is currently the most important tumor immunotherapy method. At present, immunohistochemical method are used in clinical practice to detect PD-L1 expression in tumor patients and screen for indications. However, this method is constrained by factors such as heterogeneity, dynamic changes in PD-L1 expression, and limited sample collection. PD-(L)1 PET imaging utilizes radiolabeled molecules to non-invasively assess PD-(L)1 expression in space and time, and complementary use with IHC has theoretically incomparable advantages. This article reviews the latest progress in the PD-(L)1 probe molecular imaging principles, clinical research and existing problems.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Radiological Medicine and Protection
Year:
2024
Type:
Article